Fisher Asset Management LLC Purchases 889,210 Shares of GSK PLC Sponsored ADR $GSK

Fisher Asset Management LLC grew its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 2.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 32,227,615 shares of the pharmaceutical company’s stock after acquiring an additional 889,210 shares during the quarter. Fisher Asset Management LLC owned about 1.59% of GSK worth $1,390,944,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Twin Peaks Wealth Advisors LLC bought a new stake in shares of GSK in the 2nd quarter valued at about $25,000. CNB Bank purchased a new position in GSK during the third quarter valued at approximately $31,000. CoreFirst Bank & Trust purchased a new position in GSK during the second quarter valued at approximately $33,000. MTM Investment Management LLC bought a new position in GSK in the second quarter worth approximately $37,000. Finally, Salomon & Ludwin LLC lifted its holdings in GSK by 444.0% during the third quarter. Salomon & Ludwin LLC now owns 952 shares of the pharmaceutical company’s stock worth $41,000 after buying an additional 777 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

NYSE:GSK opened at $59.06 on Monday. The company has a debt-to-equity ratio of 0.92, a current ratio of 0.82 and a quick ratio of 0.54. The company has a 50 day moving average price of $53.16 and a 200-day moving average price of $47.27. GSK PLC Sponsored ADR has a 1-year low of $32.38 and a 1-year high of $61.69. The firm has a market cap of $120.37 billion, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 3.58 and a beta of 0.44.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 9th. Shareholders of record on Friday, February 20th will be given a $0.4856 dividend. This represents a $1.94 dividend on an annualized basis and a dividend yield of 3.3%. This is an increase from GSK’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, February 20th. GSK’s payout ratio is currently 51.62%.

Insider Activity

In other GSK news, major shareholder Plc Gsk bought 1,470,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $19.00 per share, for a total transaction of $27,930,000.00. Following the transaction, the insider directly owned 18,245,691 shares of the company’s stock, valued at approximately $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a report on Wednesday, January 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of GSK in a research report on Monday, December 29th. HSBC reissued a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a report on Friday, January 16th. Finally, TD Cowen restated a “hold” rating on shares of GSK in a research report on Monday, February 9th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $44.13.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.